Pear Therapeutics is embarking on a program to provide its digital therapies for drug abuse and opioid use, re SET and re-SET-O, through telephone services.
The first telehealth offering works with digital prescription therapeutic service PursueCare, which focuses on drug addiction.
“We find that patients are often required to solve their care like a puzzle. By combining and comparing the delivery of home care systems and data, we set up a the patient at the center and bring them resources and ensure remote -sensing procedures. well, with the care of skilled doctors who can help them navigate their journey, “he said. PursueCare founder and CEO Nick Mercadante in a statement.
Pear said his employer helps patients identify providers in their state, care for the person, and discuss treatment options. It plans to add telehealth partners in the future.
Why it is
The death of a drug overdose has increased significantly in the last two years, with a significant jump in the COVID-19 disease incidence. According to the CDC, more than 100,000 people are thought to have died from a drug overdose in the 12 months ended April 2021, a nearly 29% jump compared to the previous year.
Pear is promoting its partnership with telehealth providers as a way to increase access to medication, which is not available to many with drug -using patients.
“In terms of only one in 10 Americans with drug addiction has access to some particular form of treatment. Barriers to care can include not having the medication in the person or long waiting times to get care. Pear’s ability to work with telemarketers such as PursueCare is to meet patients on their behalf, ”Pear President and CEO Dr. Corey McCann said in a statement.
“We need to make it easier for patients with addiction to seek out and learn about treatment options for relapse. By providing care and maintaining comprehensive clinical information, we can creating a balance of access, and removing problems associated with maintenance… “
THE GREAT WORK
Founded in 2013, Pear appeared in the national markets at the end of last year after the liquidation of a company with a private equity firm. In addition to its FDA -approved medications for illnesses and opioid use, the company also offers a tool for treating chronic insomnia.
Last week, Pear announced the results for the first time since going public. He met his full annual expectations of $ 4 million, bringing in $ 4.2 million last year. According to documents filed with the SEC, the company experienced a loss of $ 65.1 million in 2021.
“We’re looking at 2021 when Pear, and therefore the entire PDT segment, has its first business inflection score,” McCann said during the earnings period.